Hologic divests drug
This article was originally published in The Gray Sheet
Executive Summary
Women's health device maker divests Gestiva, its "non-core" drug for the prevention of preterm birth, to KV Pharmaceutical for $82 million in a deal announced Jan. 22. The drug, which is pending FDA approval, was part of Hologic's October purchase of cervical cancer test firm Cytyc (1"The Gray Sheet" May 28, 2007, p. 10)